LNSR · XBRL financial data

LENSAR financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LNSR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	26,382	34,459	35,358	42,164	53,494	58,435
Revenue from contracts with customers	22,781	29,493	29,443	35,716	45,962	51,656
Cost of revenue	12,307	16,626	15,403	21,057	27,643	31,313
Research and development	7,553	12,358	11,814	6,139	5,329	5,622
Selling, general and administrative	23,768	23,887	27,170	26,100	26,488	45,157
Operating income (loss)	(18,502)	(19,652)	(20,177)	(12,229)	(10,665)	(24,578)
Interest expense	1,340	—	—	—	—	—
Other income (expense)	68	51	263	698	660	636
Net income (loss)	(19,774)	(19,601)	(19,914)	(14,383)	(31,404)	(34,280)
Earnings per share, basic USD per share	—	(2.09)	(1.96)	(1.31)	(2.73)	(2.87)
Earnings per share, diluted USD per share	—	(2.09)	(1.96)	(1.31)	(2.73)	(2.87)
Weighted average shares, basic thousands of shares	—	9,374	10,159	10,971	11,518	11,958
Weighted average shares, diluted thousands of shares	—	9,374	10,159	10,971	11,518	11,958

Fiscal years (LNSR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	40,599	31,637	14,674	20,621	16,263	12,974
Short-term investments	—	—	—	3,443	6,192	5,004
Accounts receivable	2,012	4,638	6,040	4,001	6,085	6,377
Inventory	13,473	6,488	11,740	15,689	11,428	21,520
Prepaid and other current assets	1,857	1,700	1,062	2,367	1,616	601
Total current assets	58,385	44,813	33,716	46,444	41,979	46,771
Property and equipment, net	832	756	563	679	664	505
Right-of-use asset	3,668	3,151	2,630	2,141	2,466	2,556
Total assets	79,120	66,465	55,844	69,585	66,297	71,430
Accounts payable	2,481	2,694	5,422	4,007	5,995	18,982
Accrued liabilities	4,570	4,604	4,700	5,717	6,807	7,771
Total current liabilities	8,467	8,714	11,421	11,632	15,003	40,574
Lease liability, non-current	3,314	2,803	2,272	1,750	2,090	1,988
Total liabilities	11,910	11,586	13,860	22,409	47,651	83,665
Accumulated deficit	(57,993)	(77,594)	(97,508)	(111,891)	(143,295)	(177,575)
Total stockholders' equity	67,210	54,879	41,984	33,429	4,862	(26,019)
Total liabilities and equity	79,120	66,465	55,844	69,585	66,297	71,430
Common shares outstanding (cover page) thousands of shares	10,933	10,990	11,103	11,395	11,789	12,096

Fiscal years (LNSR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(19,774)	(19,601)	(19,914)	(14,383)	(31,404)	(34,280)
Stock-based compensation	9,045	6,866	6,611	5,539	2,665	3,143
Net cash from operating activities	(13,791)	(8,969)	(14,856)	(9,659)	(2,275)	(14,831)
Purchases of property and equipment	366	354	115	236	156	83
Net cash from investing activities	(326)	(354)	(115)	(4,156)	(2,161)	1,284
Proceeds from issuing common stock	16,431	—	—	—	—	—
Net cash from financing activities	50,001	361	(1,992)	19,762	78	10,258
Net change in cash	35,884	(8,962)	(16,963)	5,947	(4,358)	(3,289)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
InfuSystem Holdings	964	36,933	6,777*	19.9M	—	Q2 FY26 10-QJun 30, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026
Pulmonx	52,690	22,835	(3,183)*	43.6M	8.5 quarters	Q3 FY26 10-QSep 30, 2026
Neuronetics	22,106	41,962	1,238*	77.7M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.